Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Eight-week Double-blind, Multi-center, Randomized, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Aliskiren 75 mg, 150 mg, and 300 mg in Elderly Patients With Essential Hypertension When Given With a Light Meal

NCT00706134 is registered in ClinicalTrials.gov with Novartis as lead sponsor.

NCT NCT00706134
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00706134 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Eight-week Double-blind, Multi-center, Randomized, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Aliskiren 75 mg, 150 mg, and 300 mg in Elderly Patients With Essential Hypertension When Given With a Light Meal
Lead sponsor
Novartis
Phase
Phase 3
Overall status
Completed
Start date
May 31, 2008
Completion date
April 30, 2009
Enrollment
756 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

hypertension